Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E
J Clin Oncol. 2008 26 (13): 2178-85

PMID: 18445842 · DOI:10.1200/JCO.2007.14.8288

MeSH Terms (24)

Administration, Oral Aged Antineoplastic Agents, Alkylating Antineoplastic Combined Chemotherapy Protocols Benzenesulfonates Dacarbazine Disease-Free Survival Double-Blind Method Female Humans Infusions, Intravenous Kaplan-Meier Estimate Male Melanoma Middle Aged Neoplasm Staging Niacinamide Phenylurea Compounds Protein Kinase Inhibitors Pyridines Sorafenib Time Factors Treatment Outcome United States

Connections (1)

This publication is referenced by other Labnodes entities: